SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-190802
Filing Date
2023-07-21
Accepted
2023-07-21 06:05:59
Documents
14
Period of Report
2023-07-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d529396d8k.htm   iXBRL 8-K 23083
2 EX-99.1 d529396dex991.htm EX-99.1 17412
6 GRAPHIC g529396g0721044854151.jpg GRAPHIC 2343
  Complete submission text file 0001193125-23-190802.txt   167629

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20230721.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20230721_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20230721_pre.xml EX-101.PRE 10802
8 EXTRACTED XBRL INSTANCE DOCUMENT d529396d8k_htm.xml XML 3199
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231101028
SIC: 2834 Pharmaceutical Preparations